NR3C1 and glioblastoma: The researchers administered intratumoral glucocorticoid receptor KO anti-IL13Rα2 CAR T cells plus systemic glucocorticoids and aldesleukin in six patients with progressive/recurrent grade III or IV glioblastoma [214].